CPSE:NSIS BChemicals
Novozymes (CPSE:NSIS B) Margin Jump To 14% Tests Growth Narrative Ahead Of Q1 2026
Novozymes (CPSE:NSIS B) has opened Q1 2026 earnings season with recent quarterly revenue between €981.4 million and €1.08 billion over the past six reported periods, while quarterly EPS ranged from €0.26 to €0.40, and trailing twelve month EPS most recently sat at €1.25 on €4.16 billion of revenue. Over that stretch, revenue has moved from €3.83 billion and EPS of €1.10 on a trailing basis in Q4 2024 to €4.16 billion and EPS of €1.25 by Q4 2025. With trailing net profit margin at 14% compared...